Wednesday, October 14, 2015

Edwards Lifesciences Corporation and PULSION Medical Systems SE to dominate the Global Hemodynamic Monitoring System Market


The hemodynamic monitoring systems market has witnessed various technological advancements in the recent years. This can be attributed to the market players focusing on the introduction of newer systems to determine the hemodynamic state of a patient. A number of key players are competing against each other in order to launch new and innovative products aimed at expanding their existing customer base. These key players include Edwards Lifesciences Corporation (U.S.), PULSION Medical Systems SE (Germany), and LiDCO Group plc (U.K.). These players jointly accounted for ~65% of the total hemodynamic monitoring systems market in 2014.  


Edwards Lifesciences Corporation leads the global hemodynamic monitoring systems market. The firm has a wide portfolio in critical care monitoring, heart valves therapy, and hemodynamic monitoring. Its hemodynamic monitoring offerings comprise platforms/monitors, sensors, probes, and catheters. The hemodynamic monitoring devices represented approximately 23%, 26%, and 29% of the company sales in 2013, 2012, and 2011, respectively. The firm focuses on R&D investment to develop noninvasive and minimally invasive hemodynamic monitoring systems. In 2013, the R&D expenditure accounted for 16% ($323 million) of the company’s sales. To sell these developed products, the firm maintains both direct and indirect sales forces. In addition, the firm conducts marketing and sales activities such as educational symposia and customer training to creating awareness of its products and technologies.

PULSION Medical Systems SE is the second-largest player of the hemodynamic monitoring systems market. It offers platforms/monitors, sensors, probes, and catheters for hemodynamic monitoring based on PiCCO technology, ProAQT technology, and CeVOX technology. With a vision to offer its PiCCO technology (and CeVOX technology in some cases) for the development of integrated modular solutions for patient monitoring, the company has partnered with several leading companies in the field of perioperative monitoring such as Philips Healthcare, Dräger Medical, Mindray, and GE Healthcare. The company focuses on R&D activities to cater to the needs of its customers. In 2013, the company invested $3.05 million (6.3% of its revenue) in R&D. The company sells its products in the international markets through its own sales force and joint ventures with local partners. It has distributors located in Africa, Asia, Europe, Australia, North America, Middle East, and South America. In addition, it has built a huge network of scientists, leading clinical experts, and key opinion leaders. This network keeps the company well-informed of the latest market scenario and provides access to new distribution channels. Some of the other prominent strategic moves undertaken by leading players in the hemodynamic monitoring systems market include agreements, partnerships, joint ventures, and collaborations; and geographic expansions. Players entered into agreements, partnerships, joint ventures, and collaborations to enhance their product offerings and to distribute their products. For instance, in January 2014, Deltex Medical plc (U.K.) collaborated with Australia-based Uscom Ltd. for the distribution of USCOM 1A hemodynamic monitor in the U.K. This collaboration strengthened Uscom Ltd.’s presence in the U.K.

The players in this market adopted the strategy of geographic expansions to increase their customer base across geographies. For instance, in October 2013, Deltex Medical plc (U.K.) received FDA approval for its CardioQ-ODM+, thus increasing the company’s customer base in the U.S.
Post a Comment